Murray Lumpkin
Research Subjects
Research Interests
Murray Lumpkin has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- David Mukanga
Affiliation Bill & Melinda Gates Foundation, Seattle, Washington, United States of America
3 shared publications Aggrey Ambali
Affiliation African Union Development Agency–New Partnership for Africa’s Development, Midrand, South Africa
2 shared publicationsAyesha Khan
Affiliation Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America
2 shared publicationsBonaventure Nyabenda
Affiliation Directorate of Pharmacy, Medicines, and Laboratories, Bujumbura, Burundi
2 shared publications- Burhani Simai
Affiliation Zanzibar Food and Drug Agency, Zanzibar City, Zanzibar
2 shared publications Charles Preston
Affiliation Gates Foundation, Seattle, Washington, United States of America
2 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (9) , e0006326
Nearly one in five essential medicines fail quality standards in Africa: A systematic review and meta-analysis of MNCH medicines and antimalarials
Substandard and falsified (SF) medicines pose a major threat to maternal, newborn, and child health (MNCH) and malaria control in Africa, yet their true burden remains uncertain. We conducted a systematic review and meta-analysis of studies published between 2010 and 2025 that chemically tested the quality of essential MNCH and antimalarial medicines collected in African countries. Following PRISMA 2020 guidelines and a registered PROSPERO protocol, we searched PubMed, Embase, Web of Science, and WHO databases, screened 3,178 records, and included 123 studies from 34 countries reporting on 36,069 medicine samples. Studies were appraised with the MEDQUARG checklist, and random-effects meta-analyses with Freeman–Tukey transformation were used to estimate pooled SF prevalence overall and by therapeutic class, country, and subregion. Meta-regression explored study-level drivers of heterogeneity. Overall, 17.9% (95% CI 13.6–22.7) of tested medicines failed quality standards. Failure rates were highest for corticosteroids (65.0%), uterotonics (43.9%), and hematinics (34.7%); antimalarials, antihypertensives, and antibiotics ranged from 15-20%. Estimates for corticosteroids and hematinics carried wide confidence intervals, reflecting sparse underlying data. Western and Central Africa had the greatest regional burdens, whereas Southern Africa showed lower pooled estimates but with sparse data. Substandard medicines accounted for most poor-quality products (pooled prevalence 12.8%), while falsified medicines were less common (1.2%). Therapeutic category, geographic subregion, and use of mystery-client purchasing were significant predictors of heterogeneity, whereas publication year and methodological quality were not. Nearly one in five essential MNCH and antimalarial medicines tested in Africa are SF, posing a major barrier to reducing preventable maternal, neonatal, and child mortality. Strengthened regulatory systems, risk-based post-market surveillance, and priority attention to high-risk therapeutics, particularly uterotonics and antimalarials, are urgently needed. As the African Medicines Agency becomes operational, this evidence base offers a concrete foundation for directing continental regulatory investment where it is most needed.
- 2 September 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (9) , e0006326
Open AccessNearly one in five essential medicines fail quality standards in Africa: A systematic review and meta-analysis of MNCH medicines and antimalarials
Substandard and falsified (SF) medicines pose a major threat to maternal, newborn, and child health (MNCH) and malaria control in Africa, yet their true burden remains uncertain. We conducted a systematic review and meta-analysis of studies published between 2010 and 2025 that chemically tested the quality of essential MNCH and antimalarial medicines collected in African countries. Following PRISMA 2020 guidelines and a registered PROSPERO protocol, we searched PubMed, Embase, Web of Science, and WHO databases, screened 3,178 records, and included 123 studies from 34 countries reporting on 36,069 medicine samples. Studies were appraised with the MEDQUARG checklist, and random-effects meta-analyses with Freeman–Tukey transformation were used to estimate pooled SF prevalence overall and by therapeutic class, country, and subregion. Meta-regression explored study-level drivers of heterogeneity. Overall, 17.9% (95% CI 13.6–22.7) of tested medicines failed quality standards. Failure rates were highest for corticosteroids (65.0%), uterotonics (43.9%), and hematinics (34.7%); antimalarials, antihypertensives, and antibiotics ranged from 15-20%. Estimates for corticosteroids and hematinics carried wide confidence intervals, reflecting sparse underlying data. Western and Central Africa had the greatest regional burdens, whereas Southern Africa showed lower pooled estimates but with sparse data. Substandard medicines accounted for most poor-quality products (pooled prevalence 12.8%), while falsified medicines were less common (1.2%). Therapeutic category, geographic subregion, and use of mystery-client purchasing were significant predictors of heterogeneity, whereas publication year and methodological quality were not. Nearly one in five essential MNCH and antimalarial medicines tested in Africa are SF, posing a major barrier to reducing preventable maternal, neonatal, and child mortality. Strengthened regulatory systems, risk-based post-market surveillance, and priority attention to high-risk therapeutics, particularly uterotonics and antimalarials, are urgently needed. As the African Medicines Agency becomes operational, this evidence base offers a concrete foundation for directing continental regulatory investment where it is most needed.
- Open Access
- 3 June 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (6) , e0006576
Tiered manufacturing of pharmaceuticals as a commercial determinant of health: Implications for medicine quality and equity
Tiered manufacturing, the practice of adapting different levels of pharmaceutical production standards to low- and middle-income countries (LMICs) versus high-income countries, has not been investigated as a commercial determinant of health (CDoH), defined by the World Health Organization as a private sector activity affecting public health. This paper examines this practice and its implications for medicine quality, universal health coverage, and global health equity. Guided by the CDoH framework, we conducted semi-structured interviews with 31 mostly India-based experts in pharmaceutical development, manufacturing, procurement, and regulation between May and July 2025. Purposive sampling ensured variation in geography, organizational type, and role. Transcripts were coded deductively using CDoH domains and inductively for emergent themes. Respondents consistently described “tiered manufacturing” — using different production standards by market. Medicines for countries regulated by Stringent Regulatory Authorities (SRA) (now called WHO Listed Authorities (WLA)) adhere to international good manufacturing practices (GMP) through rigorous documentation, stability testing, impurity profiling, and advanced infrastructure. In contrast, products supplied to LMICs are often produced with uncertain GMP compliance, cheaper raw materials, weaker documentation, and less stringent oversight, leading to variable quality and shortened shelf life. Commercial drivers were key determinants. Proposed solutions include improved mechanisms to verify versions of products being received, reliance on WHO prequalification or WLA approvals, procurement conditionality and strengthened local regulatory and manufacturing capacity. Tiered manufacturing was widely perceived as a common practice among respondents. Recognition of this practice as a CDoH is essential to strengthen regulatory reliance and enforcement, procurement leverage, and sustainable capacity-building, ensuring quality medicines for all globally.
- 3 June 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (6) , e0006576
Open AccessTiered manufacturing of pharmaceuticals as a commercial determinant of health: Implications for medicine quality and equity
Tiered manufacturing, the practice of adapting different levels of pharmaceutical production standards to low- and middle-income countries (LMICs) versus high-income countries, has not been investigated as a commercial determinant of health (CDoH), defined by the World Health Organization as a private sector activity affecting public health. This paper examines this practice and its implications for medicine quality, universal health coverage, and global health equity. Guided by the CDoH framework, we conducted semi-structured interviews with 31 mostly India-based experts in pharmaceutical development, manufacturing, procurement, and regulation between May and July 2025. Purposive sampling ensured variation in geography, organizational type, and role. Transcripts were coded deductively using CDoH domains and inductively for emergent themes. Respondents consistently described “tiered manufacturing” — using different production standards by market. Medicines for countries regulated by Stringent Regulatory Authorities (SRA) (now called WHO Listed Authorities (WLA)) adhere to international good manufacturing practices (GMP) through rigorous documentation, stability testing, impurity profiling, and advanced infrastructure. In contrast, products supplied to LMICs are often produced with uncertain GMP compliance, cheaper raw materials, weaker documentation, and less stringent oversight, leading to variable quality and shortened shelf life. Commercial drivers were key determinants. Proposed solutions include improved mechanisms to verify versions of products being received, reliance on WHO prequalification or WLA approvals, procurement conditionality and strengthened local regulatory and manufacturing capacity. Tiered manufacturing was widely perceived as a common practice among respondents. Recognition of this practice as a CDoH is essential to strengthen regulatory reliance and enforcement, procurement leverage, and sustainable capacity-building, ensuring quality medicines for all globally.
- Open Access
- 23 October 2020
- Published by Springer Nature in npj Vaccines
- Vol. 5 (1) , 1-9
Navigating facilitated regulatory pathways during a disease X pandemic
In 2018, the Bill and Melinda Gates Foundation convened over thirty subject matter experts in clinical development, manufacturing, and regulatory assessment to determine how the development and approval of medical countermeasures could be accelerated in the event of Disease X. Disease X is the result of a presently unknown pathogen with epidemic or pandemic potential. A key opportunity to accelerate the scientific assessment and regulatory approval of medical countermeasures exists within efficient navigation of facilitated regulatory pathways. It was identified that not all stakeholders will be able to skillfully navigate the facilitated pathways offered by the various regulatory agencies during a public health emergency. To democratize this knowledge, we have written an overview of the facilitated approaches which have been developed and refined by Stringent Regulatory Authorities and the World Health Organization for the primary assessment of medical products. We discuss the conditions necessary for use of these approaches, scenarios in which certain pathways may be applicable, and the pros and cons of these approaches. We also address opportunities available to developers in, or developers who wish to access, low-income countries that may have nascent regulatory frameworks.
- 23 October 2020
- Published by Springer Nature in npj Vaccines
- Vol. 5 (1) , 1-9
Open AccessNavigating facilitated regulatory pathways during a disease X pandemic
In 2018, the Bill and Melinda Gates Foundation convened over thirty subject matter experts in clinical development, manufacturing, and regulatory assessment to determine how the development and approval of medical countermeasures could be accelerated in the event of Disease X. Disease X is the result of a presently unknown pathogen with epidemic or pandemic potential. A key opportunity to accelerate the scientific assessment and regulatory approval of medical countermeasures exists within efficient navigation of facilitated regulatory pathways. It was identified that not all stakeholders will be able to skillfully navigate the facilitated pathways offered by the various regulatory agencies during a public health emergency. To democratize this knowledge, we have written an overview of the facilitated approaches which have been developed and refined by Stringent Regulatory Authorities and the World Health Organization for the primary assessment of medical products. We discuss the conditions necessary for use of these approaches, scenarios in which certain pathways may be applicable, and the pros and cons of these approaches. We also address opportunities available to developers in, or developers who wish to access, low-income countries that may have nascent regulatory frameworks.
- Open Access
- 12 August 2020
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 17 (8) , e1003134
Eight years of the East African Community Medicines Regulatory Harmonization initiative: Implementation, progress, and lessons learned
Jane H. Mashingia and colleagues reveal the progress made to date for the East African Community Medicines Regulatory Harmonization initiative.
- 12 August 2020
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 17 (8) , e1003134
Open AccessEight years of the East African Community Medicines Regulatory Harmonization initiative: Implementation, progress, and lessons learned
Jane H. Mashingia and colleagues reveal the progress made to date for the East African Community Medicines Regulatory Harmonization initiative.
- Open Access
- 12 August 2020
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 17 (8) , e1003133
Coming together to improve access to medicines: The genesis of the East African Community’s Medicines Regulatory Harmonization initiative
Hiiti Sillo and colleagues reveal how the East African Community’s Medicines Regulatory Harmonization initiative improves access to important medicines in Africa.
- 12 August 2020
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 17 (8) , e1003133
Open AccessComing together to improve access to medicines: The genesis of the East African Community’s Medicines Regulatory Harmonization initiative
Hiiti Sillo and colleagues reveal how the East African Community’s Medicines Regulatory Harmonization initiative improves access to important medicines in Africa.
- 29 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (554)
Scientific considerations for global drug development
Scientific and technological advances could reduce the need for in-country or in-region confirmatory clinical trials.
- 29 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (554)
Scientific considerations for global drug development
Scientific and technological advances could reduce the need for in-country or in-region confirmatory clinical trials.
- Open Access
- 16 November 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (11) , e0166515
Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization
The United Nations Millennium Development Goals galvanized global efforts to alleviate suffering of the world’s poorest people through unprecedented public-private partnerships. Donor aid agencies have demonstrably saved millions of lives that might otherwise have been lost to disease through increased access to quality-assured vaccines and medicines. Yet, the introduction of these health interventions in low- and middle-income countries (LMICs) continues to face a time lag due to factors which remain poorly understood. A recurring theme from our partnership engagements was that an optimized regulatory process would contribute to improved access to quality health products. Therefore, we investigated the current system for medicine and vaccine registration in LMICs as part of our comprehensive regulatory strategy. Here, we report a fact base of the registration timelines for vaccines and drugs used to treat certain communicable diseases in LMICs. We worked with a broad set of stakeholders, including the World Health Organization’s prequalification team, national regulatory authorities, manufacturers, procurers, and other experts, and collected data on the timelines between first submission and last approval of applications for product registration sub-Saharan Africa. We focused on countries with the highest burden of communicable disease and the greatest need for the products studied. The data showed a typical lag of 4 to 7 years between the first regulatory submission which was usually to a regulatory agency in a high-income country, and the final approval in Sub-Saharan Africa. Two of the three typical registration steps which products undergo before delivery in the countries involve lengthy timelines. Failure to leverage or rely on the findings from reviews already performed by competent regulatory authorities, disparate requirements for product approval by the countries, and lengthy timelines by manufacturers to respond to regulatory queries were key underlying factors for the delays. We propose a series of measures which we developed in close collaboration with key stakeholders that could be taken to reduce registration time and to make safe, effective medicines more quickly available in countries where they are most needed. Many of these recommendations are being implemented by the responsible stakeholders, including the WHO prequalification team and the national regulatory authorities in Sub-Saharan Africa. Those efforts will be the focus of subsequent publications by the pertinent groups.
- 16 November 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (11) , e0166515
Open AccessSpeeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization
The United Nations Millennium Development Goals galvanized global efforts to alleviate suffering of the world’s poorest people through unprecedented public-private partnerships. Donor aid agencies have demonstrably saved millions of lives that might otherwise have been lost to disease through increased access to quality-assured vaccines and medicines. Yet, the introduction of these health interventions in low- and middle-income countries (LMICs) continues to face a time lag due to factors which remain poorly understood. A recurring theme from our partnership engagements was that an optimized regulatory process would contribute to improved access to quality health products. Therefore, we investigated the current system for medicine and vaccine registration in LMICs as part of our comprehensive regulatory strategy. Here, we report a fact base of the registration timelines for vaccines and drugs used to treat certain communicable diseases in LMICs. We worked with a broad set of stakeholders, including the World Health Organization’s prequalification team, national regulatory authorities, manufacturers, procurers, and other experts, and collected data on the timelines between first submission and last approval of applications for product registration sub-Saharan Africa. We focused on countries with the highest burden of communicable disease and the greatest need for the products studied. The data showed a typical lag of 4 to 7 years between the first regulatory submission which was usually to a regulatory agency in a high-income country, and the final approval in Sub-Saharan Africa. Two of the three typical registration steps which products undergo before delivery in the countries involve lengthy timelines. Failure to leverage or rely on the findings from reviews already performed by competent regulatory authorities, disparate requirements for product approval by the countries, and lengthy timelines by manufacturers to respond to regulatory queries were key underlying factors for the delays. We propose a series of measures which we developed in close collaboration with key stakeholders that could be taken to reduce registration time and to make safe, effective medicines more quickly available in countries where they are most needed. Many of these recommendations are being implemented by the responsible stakeholders, including the WHO prequalification team and the national regulatory authorities in Sub-Saharan Africa. Those efforts will be the focus of subsequent publications by the pertinent groups.